


*Market Scope*®

CHARTING THE COURSE  
OF THE EYE CARE MARKETS



**Products**

**E**

**E**


**E**

**R**

**R**

**D**

## 2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022



**December 2017**

9859 Big Bend Blvd., Suite 202  
Saint Louis, MO 63122  
Phone: (314) 835-0600  
Fax: (314) 835-0606  
[www.market-scope.com](http://www.market-scope.com)

## TABLE OF CONTENTS

<b>INTRODUCTION .....</b>	<b>8</b>
<i>Scope .....</i>	8
<i>Methodology .....</i>	8
About the Author .....	9
The Report at a Glance.....	10
<b>EXECUTIVE SUMMARY.....</b>	<b>11</b>
<i>The Challenges of Dry Eye Disease .....</i>	13
Dry Eye Products Market Segments.....	14
<i>Market Competitors .....</i>	16
<b>DRY EYE OVERVIEW .....</b>	<b>18</b>
Normal Tear Function .....	19
Causes of Dry Eye .....	22
DEWS Classification of Dry Eye .....	23
<i>Tear Deficiency .....</i>	23
<i>Non-Sjögren’s Tear Deficiency.....</i>	23
<i>Sjögren’s Syndrome Tear Deficiency.....</i>	24
<i>Evaporative Dry Eye.....</i>	24
The Role of Inflammation.....	26
Hormones and Dry Eye.....	26
LASIK and Dry Eye .....	28
Notes on Blepharitis.....	29
<i>Anterior Blepharitis .....</i>	29
<i>Posterior Blepharitis .....</i>	29
<b>CARE FOR DRY EYE WORLDWIDE .....</b>	<b>30</b>
Ophthalmologists .....	30
<i>Population per Ophthalmologist .....</i>	30
Optometrists.....	32
Dedicated Dry Eye Treatment Centers.....	32
<b>DRY EYE ORGANIZATIONS.....</b>	<b>35</b>
<i>Sjögren’s Syndrome Foundation .....</i>	35
<i>Tear Film and Ocular Surface Society .....</i>	35
<i>Cornea Research Foundation of America.....</i>	35
<b>DIAGNOSIS OF DRY EYE.....</b>	<b>36</b>
<i>Symptoms Versus Objective Signs .....</i>	36
Dry Eye Questionnaires .....	37
Conventional Approaches to Dry Eye Diagnosis .....	38
<i>Diagnostic Staining.....</i>	38
<i>Tear Break-up Time (TBUT).....</i>	39
<i>Schirmer Test .....</i>	40
<i>Effectiveness of Conventional Dry Eye Tests .....</i>	40

<i>Clinical Examination</i> .....	41
Newer Approaches to Dry Eye Diagnosis .....	42
<i>TearLab Osmolarity System</i> .....	42
<i>J&amp;J Vision (formerlyTearScience) LipiView Ocular Surface Interferometer</i> .....	43
<i>J&amp;J Vision LipiScan Meibomiam Imaging</i> .....	43
<i>Oculus Keratograph 5M</i> .....	44
<i>RPS/Nicox InflammDry Detector</i> .....	44
<i>Tomey Tear Stability Analysis System (TSAS)</i> .....	45
<i>Advanced Tear Diagnostics TearScan MicroAssay System</i> .....	45
<i>Bausch + Lomb (Valeant) Sjö Diagnostic Panel</i> .....	45
<i>Other New Approaches</i> .....	46
<i>DEWS on Dry Eye Diagnostics</i> .....	46
<i>The Dry Eye Diagnostic Market</i> .....	47
<b>PREVALENCE OF DRY EYE</b> .....	<b>48</b>
<i>Beaver Dam Eye Study</i> .....	48
<i>Salisbury, MD, Study</i> .....	49
<i>Extension Blue Mountains Eye Study</i> .....	49
<i>Melbourne Visual Impairment Project</i> .....	49
<i>The Canadian Dry Eye Epidemiology Study</i> .....	50
<i>Women, Menopause, Menopausal Hormone Therapy</i> .....	50
<i>Physician's Health Studies</i> .....	51
<i>Shanghai, China, Study</i> .....	51
<i>Additional Prevalence Studies</i> .....	51
<i>Estimating the Prevalence of Dry Eye Syndrome</i> .....	53
<i>Worldwide Dry Eye Populations</i> .....	56
<i>Dry Eye Populations and Contributors by Country/Category</i> .....	56
<i>United States' Dry Eye Contributors</i> .....	56
<i>Western Europe's Dry Eye Contributors</i> .....	58
<i>Japan's Dry Eye Contributors</i> .....	59
<i>Other Wealthy Nations' Dry Eye Contributors</i> .....	60
<i>China's Dry Eye Contributors</i> .....	61
<i>India's Dry Eye Contributors</i> .....	62
<i>Latin America's Dry Eye Contributors</i> .....	63
<i>Rest of World's Dry Eye Contributors</i> .....	64
<i>Dry Eye Severity</i> .....	65
<i>Treatment Frequency</i> .....	65
<i>Treated versus Untreated Dry Eye</i> .....	67
<b>OVERVIEW OF TREATMENT AND PRODUCTS</b> .....	<b>69</b>
<i>Products and Market Segments</i> .....	71
<b>DRY EYE RX PHARMACEUTICAL PRODUCTS</b> .....	<b>72</b>
<i>Anti-inflammatory Agents</i> .....	72
<i>Allergan: Restasis</i> .....	73
<i>Shire: Xiidra</i> .....	76
<i>Santen: Ikervis</i> .....	78
<i>Corticosteroids</i> .....	79

<i>Nonsteroidal Anti-inflammatories</i> .....	80
Secretagogues .....	81
<i>Santen: Diquas</i> .....	81
<i>Otsuka: Mucosta Ophthalmic</i> .....	83
Viscoelastic Lubricants .....	85
<i>Santen: Hyalein</i> .....	85
<i>TRB Chemedica: Vismed</i> .....	86
<i>Generic Sodium Hyaluronate Products</i> .....	86
Anti-infective Agents .....	86
Agents with Other Mechanisms .....	87
<i>Mitotech Russia: Vizomitin (SkQ1)</i> .....	87
Sustained-Release Rx Therapeutics .....	88
<i>Valeant Pharmaceuticals: Lacrisert</i> .....	88
Systemic Rx Therapeutics .....	88
<i>Daiichi Sankyo: Evoxac</i> .....	89
<i>Pilocarpine Agents: Salagen from Eisai and Others</i> .....	89
<b>RX PHARMA DEVELOPMENT PIPELINE</b> .....	<b>90</b>
Anti-inflammatories and Immunomodulators .....	90
<i>Allergan: Restasis X</i> .....	92
<i>Sun Pharma: Seciera</i> .....	92
<i>DH Bio/BTO Pharm: Haporine-S</i> .....	92
<i>Han Lim Pharmaceutical: Tisporin</i> .....	92
<i>Kala Pharmaceuticals: INVELTYS (KPI-121)</i> .....	93
<i>Kissei Pharmaceutical: KCT-0809</i> .....	93
<i>Novaliq: CyclASol</i> .....	93
<i>RegeneRx/G-treeBNT/ReGenTree: RGN-259</i> .....	94
HA Lubricating Rx Agents .....	95
<i>Seikagaku: SI-614</i> .....	95
Secretagogues and Other Mucin Enhancers .....	95
<i>Dong-A ST: DA-6034</i> .....	96
<i>Mimetogen Pharmaceuticals: Tavilermide (MIM-D3)</i> .....	96
Additional Therapeutic Candidates .....	98
<i>Parion Sciences: P-321</i> .....	98
<i>Sylentis: SYL-1001</i> .....	99
<i>Winston Pharmaceuticals' Civamide Nasal Solution</i> .....	99
<i>Dompé: rhNGF Eye Drops</i> .....	99
<i>KT&amp;G Life Sciences: KL7016</i> .....	100
<i>Laboratoires Théa: T2762</i> .....	100
<i>Mitotech: Vizomitin (SkQ1)</i> .....	100
Targeting Sjögren's Syndrome .....	101
<i>Novartis: VAY736</i> .....	101
US Phase III Recap .....	102
Drug Delivery .....	103
<i>InSite Vision: DuraSite 2 and ISV-101</i> .....	103
<i>Novaliq: CyclASol</i> .....	104

<i>Ocular Therapeutix: OTX-DP</i> .....	104
Stalled or Abandoned Dry Eye Product Candidates.....	105
<b>DRY EYE PROCEDURES</b> .....	<b>106</b>
Punctum Plugs.....	106
<i>Punctum Plug Applications</i> .....	107
<i>Punctum Plug Manufacturers</i> .....	107
<i>Cost of Punctum Plugs</i> .....	111
<i>Punctum Plug Development</i> .....	111
Procedures and Devices for MGD .....	112
<i>J&amp;J Vision (formerly TearScience) LipiFlow Procedure</i> .....	112
<i>MiBoMedical Group MiBoFlo ThermoFlo Procedure</i> .....	115
<i>Intense Pulsed Light (IPL)</i> .....	115
<i>Gulden Ophthalmics MG Expressor Kit</i> .....	116
<i>Laboratoires Théa Blephasteam</i> .....	116
<i>Rhein Medical's Maskin Meibomian Gland Intraductal Probe</i> .....	116
<i>RySurg's BlephEx</i> .....	116
Tissue Engineering and Regeneration .....	117
<i>Bio-Tissue's ProKera</i> .....	117
<i>Katena/IOP Ophthalmics' Dehydrated Amniotic Membrane</i> .....	117
Reservoir and Hydration-based Procedures and Devices.....	118
<i>Boston Foundation for Sight's PROSE Treatment</i> .....	118
<i>Blanchard Contact Lenses Onefit</i> .....	119
Alternative Technologies.....	119
<i>Allergan's TrueTear Nueronasal Stimulator</i> .....	119
Investigational Procedures and Devices.....	120
<i>Lacrimal Abdominal Reservoir</i> .....	120
<i>Tear Film Innovations: iLux</i> .....	120
<b>OTC LUBRICATING PRODUCTS</b> .....	<b>121</b>
<i>Lubricating Drops</i> .....	121
<i>Ointments and Gels</i> .....	121
Leading Artificial Tear Products.....	121
<i>Alcon (Novartis): Systane</i> .....	121
<i>Allergan: Refresh and Optive</i> .....	123
<i>J&amp;J Vision: Blink Tears</i> .....	124
<i>Bausch + Lomb: Soothe and Advanced Eye Relief</i> .....	124
<i>Akorn's TheraTears</i> .....	125
<i>Oasis Medical's Oasis Tears</i> .....	125
<i>Johnson &amp; Johnson's Visine</i> .....	125
Additional Artificial Tears Products .....	126
<i>Novaliq: NovaTears</i> .....	126
<i>OCuSOFT's Retaine</i> .....	126
<i>OCuSOFT: Tears Again</i> .....	127
<i>Paragon BioTeck: EqualEyes</i> .....	127
<i>Santen/Novagali: Cationorm</i> .....	127
<i>Similasan: Dry Eye Relief</i> .....	128

<i>Spectrum Thea: Thealoz</i> .....	128
<i>New Developments</i> .....	128
Composition and Classification .....	128
<i>Chemical Composition of Lubricating Tears and Gels</i> .....	128
<i>Preservative Use in Lubricating Tears and Gels</i> .....	129
<i>Classification by Packaging</i> .....	132
Hybrid OTC/Rx Lubricants .....	134
<i>TRB Chemedica's Vismed</i> .....	135
<i>Allergan's Optava</i> .....	136
<b>GLOBAL DRY EYE MARKET FORECASTS</b> .....	<b>137</b>
<i>Global Market for Dry Eye Products</i> .....	137
<i>Company Market Share</i> .....	140
The Rx Market Segment .....	141
<i>Forecast for the Rx Product Market Segment</i> .....	143
<i>Company Market Share in Rx Segment</i> .....	146
The Procedure Market Segment .....	147
<i>The Market in Newer Procedures</i> .....	149
<i>Forecast for the Punctum Plug Market Segment</i> .....	151
OTC Market Segment .....	153
<i>Forecast for the OTC Market Segment</i> .....	153
<i>Company Market Share in the OTC Segment</i> .....	157
<b>OTHER DRY EYE PRODUCTS, PROCEDURES</b> .....	<b>158</b>
OTC Nutritional Supplementation .....	158
<i>Studies</i> .....	158
<i>TRB Chemedica's Remogen Omega</i> .....	159
<i>ScienceBased Health's HydroEye SoftGels</i> .....	159
<i>BioSyntrx' BioTears Oral Gel Caps</i> .....	159
<i>Akorn's TheraTears Nutrition</i> .....	160
<i>Other Supplements</i> .....	160
Other Dry Eye Treatments .....	160
<i>Autologous Serum Eye Drops</i> .....	160
<i>Lateral Tarsorrhaphy</i> .....	160
<i>Moisture Shielding Eyewear</i> .....	161
<b>COMPANY PROFILES</b> .....	<b>162</b>
Company Share in the Dry Eye Market .....	162
Akorn, Inc. ....	163
Alcon, Inc. ....	164
Allergan plc .....	165
Bausch + Lomb .....	166
Beaver-Visitec International, Inc. ....	167
BioSyntrx, Inc. ....	168
Bio-Tissue, Inc. ....	169
Eagle Vision, Inc. ....	170
FCI Ophthalmics .....	171
Gulden Ophthalmics .....	172

Johnson & Johnson Vision.....	173
Kala Pharmaceuticals .....	174
Katena Products.....	175
Laboratoires Théa .....	176
Lacrimedics, Inc. ....	177
Medennium, Inc.....	178
Mimetogen Pharmaceuticals.....	179
Oasis Medical, Inc.....	180
OCuSOFT, Inc. ....	181
Ocular Therapeutix .....	182
Otsuka Pharmaceutical Co., Ltd. ....	183
Rhein Medical, Inc. ....	184
Santen Pharmaceutical Co., Ltd. ....	185
ScienceBased Health, Inc.....	186
Senju Pharmaceutical Co., Ltd. ....	187
Shire Plc.....	188
Similasan.....	189
Sun Pharmaceutical Industries, Inc. ....	190
Surgical Specialties Corporation.....	191
Tear Film Innovations .....	192
TearLab Corporation.....	193
TRB Chemedica International S.A.....	194
<b>INDEX OF TABLES .....</b>	<b>195</b>
<b>INDEX OF FIGURES.....</b>	<b>196</b>

## INTRODUCTION

Market Scope's *2017 Dry Eye Products Report* analyzes the current marketplace and forecasts market performance over the next five years. The report is designed to provide value to members of the ophthalmic industry who participate in the dry eye products market, providers of dry eye treatment, market analysts, investors, and any other parties interested in dry eye treatments or related products.

### **Scope**

We use eight categories defined by region and economics in our analysis: the United States, Western Europe, Japan, Other Wealthy Nations (OWN), China, India, Latin America, and Rest of World (ROW). Our OWN category is made up of a mix of nations with higher per-capita gross domestic products throughout the world—Canada, South Korea, and the United Arab Emirates are examples. The ROW category is a catch-all category for nations not included elsewhere. ROW nations have diverse economies and a significant range of development levels. Namibia, Indonesia, Turkey, and Russia are examples.

Our report is designed to provide depth and context to the reader's understanding of market dynamics in this ophthalmic segment. Our coverage includes:

- Overview of dry eye disease
- Diagnosis and treatment of dry eye
- A global view of dry eye care providers
- Current estimates and five-year forecasts for dry eye in our eight analytic categories
- Dry eye Rx products in the marketplace
- Devices and procedures used to treat dry eye
- OTC products for dry eye
- Investigational agents in the development pipeline
- Profiles of companies developing, making, and marketing dry eye products

### **Methodology**

Data and forecasts in our report span 2016 through 2022. We use both primary and secondary sources for the data and information. These include:

- Market Scope surveys of ophthalmologists
- Market Scope's proprietary disease models
- Interviews with executives from companies in the market segment
- Interviews with product development teams
- Published medical research
- Research presentations at ophthalmic meetings

**Copyright © 2017 Market Scope®**

**No part of this document may be reproduced without  
written permission from the publisher.**